| Beth B Herrick, MD | |
|
736 Cambridge St, Brighton, MA 02135-2907 | |
| (617) 789-3232 | |
| Not Available |
| Full Name | Beth B Herrick |
|---|---|
| Gender | Female |
| Speciality | Radiation Oncology |
| Experience | 38 Years |
| Location | 736 Cambridge St, Brighton, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548229016 | NPI | - | NPPES |
| 110057739A | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | 150973 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Elizabeth's Medical Center | Brighton, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Steward Medical Group Inc | 2860688728 | 1404 |
News Archive
People who use proton pump inhibitors (PPIs) are up to 21% more likely to experience a heart attack than people who do not use the antacids, according to researchers from Stanford University, California.
Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding, according to new research involving UT Southwestern Medical Center and 28 other medical institutions.
Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down cells with specific targets on them to treat cancer, researchers at The University of Texas MD Anderson Cancer Center report in the journal Leukemia.
New performance measures have been developed for patients on warfarin that may save lives and money.
Canadians can expect to benefit from more targeted investments in cancer screening and treatment as a result of a first-of-its-kind initiative that is standardizing the collection of cancer stage information across Canada. The initiative marks a change that cancer experts have wanted for more than 20 years, and that will help cancer system decision-makers to target areas of greatest need in cancer control.
› Verified 4 days ago
| Entity Name | Dana-farber Cancer Institute, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851333686 PECOS PAC ID: 9133038904 Enrollment ID: O20040223000228 |
News Archive
People who use proton pump inhibitors (PPIs) are up to 21% more likely to experience a heart attack than people who do not use the antacids, according to researchers from Stanford University, California.
Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding, according to new research involving UT Southwestern Medical Center and 28 other medical institutions.
Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down cells with specific targets on them to treat cancer, researchers at The University of Texas MD Anderson Cancer Center report in the journal Leukemia.
New performance measures have been developed for patients on warfarin that may save lives and money.
Canadians can expect to benefit from more targeted investments in cancer screening and treatment as a result of a first-of-its-kind initiative that is standardizing the collection of cancer stage information across Canada. The initiative marks a change that cancer experts have wanted for more than 20 years, and that will help cancer system decision-makers to target areas of greatest need in cancer control.
› Verified 4 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000007 |
News Archive
People who use proton pump inhibitors (PPIs) are up to 21% more likely to experience a heart attack than people who do not use the antacids, according to researchers from Stanford University, California.
Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding, according to new research involving UT Southwestern Medical Center and 28 other medical institutions.
Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down cells with specific targets on them to treat cancer, researchers at The University of Texas MD Anderson Cancer Center report in the journal Leukemia.
New performance measures have been developed for patients on warfarin that may save lives and money.
Canadians can expect to benefit from more targeted investments in cancer screening and treatment as a result of a first-of-its-kind initiative that is standardizing the collection of cancer stage information across Canada. The initiative marks a change that cancer experts have wanted for more than 20 years, and that will help cancer system decision-makers to target areas of greatest need in cancer control.
› Verified 4 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000332 |
News Archive
People who use proton pump inhibitors (PPIs) are up to 21% more likely to experience a heart attack than people who do not use the antacids, according to researchers from Stanford University, California.
Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding, according to new research involving UT Southwestern Medical Center and 28 other medical institutions.
Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down cells with specific targets on them to treat cancer, researchers at The University of Texas MD Anderson Cancer Center report in the journal Leukemia.
New performance measures have been developed for patients on warfarin that may save lives and money.
Canadians can expect to benefit from more targeted investments in cancer screening and treatment as a result of a first-of-its-kind initiative that is standardizing the collection of cancer stage information across Canada. The initiative marks a change that cancer experts have wanted for more than 20 years, and that will help cancer system decision-makers to target areas of greatest need in cancer control.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Beth B Herrick, MD Po Box 415348, Boston, MA 02241-5348 Ph: (800) 225-8885 | Beth B Herrick, MD 736 Cambridge St, Brighton, MA 02135-2907 Ph: (617) 789-3232 |
News Archive
People who use proton pump inhibitors (PPIs) are up to 21% more likely to experience a heart attack than people who do not use the antacids, according to researchers from Stanford University, California.
Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding, according to new research involving UT Southwestern Medical Center and 28 other medical institutions.
Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down cells with specific targets on them to treat cancer, researchers at The University of Texas MD Anderson Cancer Center report in the journal Leukemia.
New performance measures have been developed for patients on warfarin that may save lives and money.
Canadians can expect to benefit from more targeted investments in cancer screening and treatment as a result of a first-of-its-kind initiative that is standardizing the collection of cancer stage information across Canada. The initiative marks a change that cancer experts have wanted for more than 20 years, and that will help cancer system decision-makers to target areas of greatest need in cancer control.
› Verified 4 days ago
Richard Faraci, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 736 Cambridge St, Brighton, MA 02135 Phone: 617-789-3000 | |
Allison L Keel, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 736 Cambridge St, Brighton, MA 02135 Phone: 617-789-2740 | |
Alpa Garg, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 736 Cambridge St, Brighton, MA 02135 Phone: 617-789-2740 | |
James Hill, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 20 Guest St Ste 225, Brighton, MA 02135 Phone: 617-738-8642 Fax: 617-202-4172 | |
Yael Vin, MD Radiology Medicare: Medicare Enrolled Practice Location: 116 North Beacon Street, Brighton, MA 02135 Phone: 617-783-5200 Fax: 617-783-5202 | |
Dr. Saurabh Pallod, MBBS Radiology Medicare: Not Enrolled in Medicare Practice Location: 1 Bronsdon St Apt 1b-c, Brighton, MA 02135 Phone: 508-596-6259 |